Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
| Horizon | Bear case (−1σ) | Base case | Bull case (+1σ) |
|---|---|---|---|
| 1 Month | $3.82 (-18.4%) | $4.68 | $5.73 (+22.5%) |
| 3 Months | $3.29 (-29.6%) | $4.68 | $6.65 (+42.1%) |
| 6 Months | $2.85 (-39.1%) | $4.68 | $7.69 (+64.3%) |
| 12 Months | $2.32 (-50.5%) | $4.68 | $9.45 (+101.9%) |